Holen Sie sich die Stockscreener-App
17.20
8.22%
-1.54
Handel nachbörslich:
17.20
Schlusskurs vom Vortag:
$18.74
Offen:
$18.04
24-Stunden-Volumen:
2.15M
Relative Volume:
3.15
Marktkapitalisierung:
$1.31B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.16M
KGV:
-13.54
EPS:
-1.2702
Netto-Cashflow:
$-69.06M
1W Leistung:
-34.90%
1M Leistung:
-30.65%
6M Leistung:
-53.04%
1J Leistung:
-54.44%
1-Tages-Spanne:
$16.64
$18.55
1-Wochen-Bereich:
$16.64
$26.82
52-Wochen-Spanne:
$16.64
$46.99
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Vergleichen Sie CGON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
17.20 | 1.31B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
Q1 Earnings Estimate for CG Oncology Issued By HC Wainwright - Defense World
HC Wainwright Forecasts CG Oncology FY2029 Earnings - Defense World
Cantor Fitzgerald Weighs in on CG Oncology FY2025 Earnings - Defense World
CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (NASDAQ:CGON) - Seeking Alpha
Teacher Retirement System of Texas Acquires Shares of 11,927 CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade - MSN
Relative Strength Alert For CG Oncology - Nasdaq
CG Oncology stock hits 52-week low at $23.9 amid challenges - Investing.com UK
CG Oncology (NASDAQ:CGON) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright maintains CG Oncology stock Buy rating, $75 target By Investing.com - Investing.com Canada
Practice-Changing Bladder Cancer Results: Key BOND-003 Trial Data Revealed at Major Urology Conference - Stock Titan
CG Oncology announces mixed shelf offering - MSN
CG Oncology Advances in Bladder Cancer Therapeutics - MSN
CG Oncology Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
CG Oncology Inc Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing - MarketScreener
CG Oncology, Inc. SEC 10-K Report - TradingView
CG Oncology Reports 2024 Year End Financial Results And Provides Business Updates - Marketscreener.com
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - The Manila Times
Swiss National Bank Has $2.28 Million Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey
CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains CG Oncology buy with $75 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains CG Oncology buy with $75 target - Investing.com India
Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts - Benzinga
CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial - Marketscreener.com
Cretostimogene shows promise in bladder cancer study By Investing.com - Investing.com Australia
Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund - Endpoints News
Cretostimogene shows promise in bladder cancer study - Investing.com India
CG Oncology Reports Promising BOND-003 Data: 75.5% Complete Response Rate for Cretostimogene in Bladder Cancer Treatment - Nasdaq
Breakthrough: Novel Bladder Cancer Drug Shows 75% Response Rate with 28-Month Durability - Stock Titan
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Decreases Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Tuesday - Defense World
CG Oncology (NASDAQ:CGON) Stock Price Up 7.3% – Time to Buy? - Defense World
11,853 Shares in CG Oncology, Inc. (NASDAQ:CGON) Purchased by Arizona State Retirement System - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Given Average Recommendation of “Buy” by Analysts - The AM Reporter
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Cg Oncology Inc (CGON): A Sitting Duck With -181.74% Upside Potential - Stocks Register
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates - The Manila Times
CG Oncology to Present Late-Breaking Abstract and Key Research on Cretostimogene Grenadenorepvec at 40th Annual EAU Congress - Nasdaq
Major Clinical Trial Results: CG Oncology Unveils New Bladder Cancer Treatment Data at European Congress - StockTitan
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Morgan Stanley - Defense World
3 Analysts Assess CG Oncology: What You Need To Know - Benzinga
Oncolytic Adenovirus Market Set to Grow Substantially Through 2032, DelveInsight Projects | CG Oncology, Orca Therapeutics B.V., Syneos Health, DNAtrix, Inc. - Barchart
Oncolytic Adenovirus Market Set to Grow Substantially Through - openPR
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug - Benzinga
New York State Common Retirement Fund Grows Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Cg Oncology Inc (CGON) is looking forward to a strong quarter - SETE News
CG Oncology stock hits 52-week low at $24.15 amid challenges - Investing.com India
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Rhumbline Advisers - Defense World
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):